INT206704

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.39
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 4
Disease Relevance 5.18
Pain Relevance 0.30

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytoplasm (KDR, VEGFA) extracellular region (KDR, VEGFA) extracellular space (VEGFA)
growth (VEGFA) proteinaceous extracellular matrix (VEGFA) nucleus (KDR)
Anatomy Link Frequency
endothelial cells 6
KDR (Homo sapiens)
VEGFA (Homo sapiens)
Pain Link Frequency Relevance Heat
cva 2 78.72 Quite High
Central nervous system 1 78.28 Quite High
headache 2 74.48 Quite High
abdominal pain 1 74.08 Quite High
Pain 4 71.48 Quite High
imagery 9 40.48 Quite Low
dexamethasone 11 5.00 Very Low Very Low Very Low
metalloproteinase 8 5.00 Very Low Very Low Very Low
Chronic pancreatitis 4 5.00 Very Low Very Low Very Low
positron emission tomography 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hematologic Neoplasms 14 98.12 Very High Very High Very High
Carcinoma 15 97.24 Very High Very High Very High
Colon Cancer 33 97.08 Very High Very High Very High
Myelofibrosis 11 95.56 Very High Very High Very High
Myelodysplastic Syndromes 11 95.24 Very High Very High Very High
Camurati-engelmann Disease 6 94.36 High High
Myeloproliferative Disorder 13 91.12 High High
Ovarian Cancer 122 86.48 High High
Hyperlipidemia 1 82.32 Quite High
Apoptosis 19 81.40 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Anti-angiogenic therapies are mostly based on inhibiting the binding of VEGF to VEGFR by neutralizing antibodies to the ligand or to the receptor, soluble receptors, small molecule inhibitors or are directed against the tyrosine kinase activity of the VEGF receptors (Figure 1).
Negative_regulation (inhibiting) of VEGFR Binding (binding) of VEGF
1) Confidence 0.39 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2902424 Disease Relevance 1.74 Pain Relevance 0
Bevacizumab prevents interaction of VEGF with VEGFR1 (FLT-1) and VEGFR2 (KDR) on the surface of endothelial cells to inhibit angiogenesis.
Negative_regulation (prevents) of KDR Binding (interaction) of VEGF in endothelial cells
2) Confidence 0.20 Published 2007 Journal Mol Cancer Section Body Doc Link PMC1852117 Disease Relevance 0.79 Pain Relevance 0
Ramucirumab (IMC-1121B) is a fully human antibody that blocks the interaction between VEGF and VEGFR2, resulting in potent inhibition of an array of biological activities of VEGF, including activation of the receptor and its signaling pathway, intracellular calcium mobilization, and migration and proliferation of endothelial cells [52].
Negative_regulation (blocks) of VEGFR2 Binding (interaction) of VEGF in endothelial cells
3) Confidence 0.14 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2804796 Disease Relevance 1.86 Pain Relevance 0.30
Bevacizumab prevents interaction of VEGF with VEGFR1 (FLT-1) and VEGFR2 (KDR) on the surface of endothelial cells to inhibit angiogenesis.
Negative_regulation (prevents) of VEGFR2 Binding (interaction) of VEGF in endothelial cells
4) Confidence 0.09 Published 2007 Journal Mol Cancer Section Body Doc Link PMC1852117 Disease Relevance 0.79 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox